How Do Cardiac Myosin Inhibitors Treat HCM Symptoms?
At a Glance
Cardiac myosin inhibitors, such as mavacamten and aficamten, treat hypertrophic cardiomyopathy (HCM) by targeting hyperactive proteins to help the heart muscle relax. They require strict monitoring through regular echocardiograms to ensure the heart's pumping power doesn't drop too low.
In this answer
4 sections
Cardiac myosin inhibitors, such as mavacamten (Camzyos) and aficamten, are a newer class of medications designed to treat the root cause of hypertrophic cardiomyopathy (HCM). In HCM, genetic changes cause the proteins in the heart muscle to become overactive, leading the heart to squeeze too hard—a condition known as hypercontractility [1][2][3]. While traditional medications like beta-blockers work primarily by slowing the heart rate to give the heart more time to fill with blood [4][5][6], cardiac myosin inhibitors work directly inside the muscle cells. They target the specific proteins responsible for the heart’s contraction, helping the hyperactive heart muscle relax and function more normally [7][8][9].
How Traditional Beta-Blockers Work
For many years, beta-blockers (such as metoprolol) have been the standard first-line treatment for managing symptoms of HCM [4][6]. They help relieve symptoms by blocking the effects of adrenaline on the heart. This action reduces the heart rate and the force of contraction, which gives the stiffened heart chambers more time to relax and fill with blood between beats [4][5][6]. While highly effective at managing symptoms for many people, beta-blockers do not fix the underlying mechanical flaw. Because of this, cardiac myosin inhibitors are often prescribed to patients who are still experiencing limiting symptoms despite taking standard beta-blockers, and your doctor will decide whether to add these new drugs to your regimen or use them as a replacement [10][11].
Targeting the Root Cause: Cardiac Myosin Inhibitors
Inside your heart muscle cells are tiny protein fibers called myosin and actin. In a healthy heart, these fibers latch onto each other (creating “cross-bridges”) to make the heart muscle contract, and then release each other to let the heart relax. In HCM, the myosin proteins are stuck in the “on” position, creating too many cross-bridges [1][3]. This means the heart is constantly working too hard and cannot relax properly.
Medications like mavacamten and aficamten attach directly to the myosin proteins and stabilize them in their “off” or resting state [12][13][14]. By preventing excessive cross-bridges from forming, these drugs reduce the abnormal squeezing force, lower the pressure inside the heart, and relieve the obstruction of blood flow out of the heart [15][16][17]. This often leads to significant improvements in energy, exercise capacity, and daily symptoms [18][19][20].
Heart Failure Risks and Reversibility
Because cardiac myosin inhibitors are highly effective at relaxing the heart muscle, there is a risk that they could relax it too much. If the heart’s pumping power—measured as the left ventricular ejection fraction (LVEF)—drops too low, it can mimic heart failure, where the heart cannot pump enough blood to meet the body’s needs [21][22][23].
Fortunately, clinical evidence shows that if the pumping power drops, this effect is generally reversible. By pausing the medication or lowering the dose under the guidance of your doctor, the heart’s pumping strength typically recovers [21][24][25].
Strict Monitoring and Severe Drug Interactions
To safely manage these risks, these medications require highly specialized monitoring and strict safety protocols:
- Frequent Echocardiograms: Before starting, and regularly throughout treatment, patients must undergo an echocardiogram (an ultrasound of the heart) to measure their ejection fraction [15][21][26]. This is a significant time commitment—often requiring monthly scans when you first start, then spacing out to every few months.
- REMS Program: Mavacamten is only available through a strict safety program called Risk Evaluation and Mitigation Strategy (REMS) to ensure consistent safety monitoring [27][28][29]. Aficamten, an investigational drug in late-stage development, requires similar echocardiogram-guided dosing but does not currently fall under the formal mavacamten REMS [21][30][15].
- Severe Drug Interactions: Mavacamten interacts heavily with common medications processed by certain liver enzymes (CYP2C19 and CYP3A4). Taking mavacamten alongside certain heartburn medicines (like omeprazole), antibiotics, or antifungals can dangerously increase the levels of mavacamten in your blood, precipitating heart failure [31][32][33]. You must consult your doctor or pharmacist before starting, stopping, or changing any medication, including over-the-counter drugs and supplements.
- Warning Signs: Between scans, patients must be vigilant. If you experience sudden shortness of breath, new swelling in the legs, or rapid weight gain, contact your care team immediately, as these can be signs that your heart muscle is relaxing too much.
Common questions in this guide
How do cardiac myosin inhibitors work differently from beta-blockers?
What is the main risk of taking a cardiac myosin inhibitor?
Can I take other medications while on mavacamten?
What warning signs should I watch for while taking cardiac myosin inhibitors?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my current symptoms and response to beta-blockers, am I a good candidate to add or switch to a cardiac myosin inhibitor?
- 2.If we start a medication like mavacamten, what will my specific echocardiogram monitoring schedule look like for the first year, and what is the time commitment required?
- 3.How will my current medications, including over-the-counter heartburn or allergy medicines, interact with a cardiac myosin inhibitor?
- 4.What specific warning signs of heart failure should I watch for between my scheduled echocardiograms?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (33)
- 1
Cryo-EM structure of the folded-back state of human β-cardiac myosin.
Grinzato A, Auguin D, Kikuti C, et al.
Nature communications 2023; (14(1)):3166 doi:10.1038/s41467-023-38698-w.
PMID: 37258552 - 2
β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity.
Adhikari AS, Trivedi DV, Sarkar SS, et al.
Nature communications 2019; (10(1)):2685 doi:10.1038/s41467-019-10555-9.
PMID: 31213605 - 3
Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition.
Robert-Paganin J, Auguin D, Houdusse A
Nature communications 2018; (9(1)):4019 doi:10.1038/s41467-018-06191-4.
PMID: 30275503 - 4
Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.
Dicorato MM, Citarelli G, Mangini F, et al.
Biomedicines 2025; (13(5)) doi:10.3390/biomedicines13051256.
PMID: 40427081 - 5
Beta blockers and hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis.
Smith AJ, Cromie AMM, Bowles L, et al.
Open heart 2025; (12(2)) doi:10.1136/openhrt-2025-003460.
PMID: 41136226 - 6
The Diagnosis and Treatment of Hypertrophic Cardiomyopathy.
Möbius-Winkler MN, Laufs U, Lenk K
Deutsches Arzteblatt international 2024; (121(24)):805-811.
PMID: 39377928 - 7
CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.
Desai MY, Michaud V, Thacker D, et al.
Expert opinion on drug safety 2026; (25(5)):813-822 doi:10.1080/14740338.2025.2596231.
PMID: 41313044 - 8
Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.
Młynarska E, Radzioch E, Dąbek B, et al.
Biomedicines 2024; (12(12)) doi:10.3390/biomedicines12122675.
PMID: 39767581 - 9
Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.
Halder R, Warshel A
Protein science : a publication of the Protein Society 2025; (34(10)):e70289 doi:10.1002/pro.70289.
PMID: 40944412 - 10
Cardiac myosin inhibitors in hypertrophic cardiomyopathy.
Lim J, Kim HK
Journal of cardiovascular imaging 2025; (33(1)):7 doi:10.1186/s44348-025-00052-7.
PMID: 40624601 - 11
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT, Jacoby D, Elliott PM, et al.
European journal of heart failure 2023; (25(2)):260-270 doi:10.1002/ejhf.2737.
PMID: 36404399 - 12
Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease.
Parums DV
Medical science monitor : international medical journal of experimental and clinical research 2025; (31()):e951868 doi:10.12659/MSM.951868.
PMID: 41174905 - 13
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
Woodland M, Al-Horani RA
Cardiovascular & hematological agents in medicinal chemistry 2023; (21(2)):78-83 doi:10.2174/1871525721666221019095218.
PMID: 36278454 - 14
Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin.
Rohde JA, Roopnarine O, Thomas DD, Muretta JM
Proceedings of the National Academy of Sciences of the United States of America 2018; (115(32)):E7486-E7494 doi:10.1073/pnas.1720342115.
PMID: 30018063 - 15
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects.
Hou L, Lin B, Ji X, Huang A
Drug design, development and therapy 2025; (19()):9367-9385 doi:10.2147/DDDT.S555335.
PMID: 41127363 - 16
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Maron MS, Gimeno JR, Veselka J, et al.
European heart journal 2025; (46(40)):4076-4086 doi:10.1093/eurheartj/ehaf364.
PMID: 41120118 - 17
Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials.
Fahim M, Eldawud D, Wahadneh O, et al.
The American journal of cardiology 2026; (265()):50-56 doi:10.1016/j.amjcard.2026.02.018.
PMID: 41672217 - 18
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Wang A, Garcia-Pavia P, Masri A, et al.
Journal of the American College of Cardiology 2026; (87(8)):1029-1042 doi:10.1016/j.jacc.2025.10.057.
PMID: 41348072 - 19
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Hegde SM, Wang X, Garcia-Pavia P, et al.
Journal of the American College of Cardiology 2025; (86(24)):2452-2467 doi:10.1016/j.jacc.2025.08.022.
PMID: 40932433 - 20
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Garcia-Pavia P, Maron MS, Masri A, et al.
The New England journal of medicine 2025; (393(10)):949-960 doi:10.1056/NEJMoa2504654.
PMID: 40888697 - 21
Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials.
Felix N, Teixeira L, Nogueira A, et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2025; (25(3)):361-371 doi:10.1007/s40256-024-00710-z.
PMID: 39681736 - 22
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.
Aman A, Akram A, Akram B, et al.
Open heart 2025; (12(1)) doi:10.1136/openhrt-2025-003215.
PMID: 39988344 - 23
The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review.
Yassen M, Changal K, Busken J, et al.
The American journal of cardiology 2024; (210()):219-224 doi:10.1016/j.amjcard.2023.10.059.
PMID: 37884110 - 24
A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin.
Pugsley MK, Hwee DT, Winters BR, et al.
International journal of toxicology 2025; (44(3)):211-234 doi:10.1177/10915818251326466.
PMID: 40112881 - 25
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Hegde SM, Claggett BL, Wang X, et al.
Journal of the American College of Cardiology 2024; (84(19)):1789-1802 doi:10.1016/j.jacc.2024.08.002.
PMID: 39217556 - 26
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
Merali S, Salinger DH, Palmisano M, et al.
CPT: pharmacometrics & systems pharmacology 2024; (13(9)):1448-1461 doi:10.1002/psp4.13138.
PMID: 38695527 - 27
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program.
Desai MY, Seto D, Cheung M, et al.
Circulation. Heart failure 2025; (18(1)):e012441 doi:10.1161/CIRCHEARTFAILURE.124.012441.
PMID: 39523955 - 28
Outcomes of a multidisciplinary approach to management of mavacamten in obstructive hypertrophic cardiomyopathy.
Jensen H, Yousif Z, Huynh T, et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2025; (82(7)):e384-e390 doi:10.1093/ajhp/zxae372.
PMID: 39611751 - 29
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center.
Desai MY, Hajj-Ali A, Rutkowski K, et al.
Progress in cardiovascular diseases 2024; (86()):62-68 doi:10.1016/j.pcad.2024.02.001.
PMID: 38354765 - 30
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Davis BJ, Volk H, Nguyen O, et al.
Journal of the American Heart Association 2025; (14(6)):e038758 doi:10.1161/JAHA.124.038758.
PMID: 40055855 - 31
Exposure-Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM.
Merali S, Bunn H, Sychterz C, et al.
Journal of clinical pharmacology 2025; (65(12)):1802-1814 doi:10.1002/jcph.70072.
PMID: 40796530 - 32
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M, Sychterz C, Perera V, et al.
Clinical pharmacology and therapeutics 2023; (114(4)):922-932 doi:10.1002/cpt.3005.
PMID: 37467157 - 33
Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS.
Li Q, Liu YN, Chen C, et al.
Chemico-biological interactions 2023; (380()):110531 doi:10.1016/j.cbi.2023.110531.
PMID: 37150496
This information on cardiac myosin inhibitors is for educational purposes only. Always consult your cardiologist before changing medications or if you experience new symptoms.
Get notified when new evidence is published on Hypertrophic Cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.